Buy CHRS by Oct 20, 2026.

Title: Coherus BioSciences' Aggressive Hiring Spree: Financial Desperation or Pipeline Confidence? How is it possible for a company that the market treats as practically bankrupt to aggressively expand its commercial sales network? To the average investor looking at Coherus BioSciences (NASDAQ: CHRS), the math simply does not seem to add up. The stock has been trading at severely depressed levels, the company recently sold off its main cash-cow biosimilars, and it currently relies on just a single approved innovative drug, …